To include your compound in the COVID-19 Resource Center, submit it here.

Eisai, Ono to conduct Phase Ib HCC trial for Lenvima and Opdivo

Eisai Co. Ltd. (Tokyo:4523) and Ono Pharmaceutical Co. Ltd. (Tokyo:4528) partnered to conduct a Japanese Phase

Read the full 165 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE